4/A: Eyenovia Director Charles E. Mather IV Corrects Beneficial Ownership Report After Reverse Stock Split and Pending Business Combination

Charles E. Mather IV, a director at Eyenovia, Inc., files an amended Form 4/A to correct a clerical error in a previous filing regarding his securities ownership, following a reverse stock split and in anticipation of a business combination with Betaliq, Inc.

Summary

• Charles E. Mather IV, a director of Eyenovia, Inc. (EYEN), filed an amended Form 4/A with the SEC to correct a clerical error in a previously submitted Form 4.
• The original filing incorrectly reported the amount of securities beneficially owned by Mather.
• The corrected filing reflects changes due to a 1-for-80 reverse stock split that Eyenovia implemented on January 31, 2025.
• Mather acquired 8,000 restricted stock units on April 21, 2025, at a price of $0.
• These restricted stock units will fully vest upon the closing of Eyenovia's proposed business combination with Betaliq, Inc., contingent upon Mather's continued service to Eyenovia.
• Following the reported transactions, Mather beneficially owns 9,950 shares of Eyenovia common stock.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a clerical error. The pending business combination is a positive development, but the filing itself is neutral in sentiment.

Future Outlook

The vesting of the restricted stock units is contingent upon the closing of Eyenovia's proposed business combination with Betaliq, Inc. and Mather's continued service to the Issuer.

Management Comments

• This Form 4/A is being filed to correct a clerical error in the original Form 4 filed on 04/23/2025.
• The original filing incorrectly reported the amount of securities beneficially owned by the Reporting Person.
• All other information in the original filing remains unchanged.

Industry Context

Form 4 filings are standard practice for company insiders (directors, officers, and principal stockholders) to report transactions in their company's stock to the SEC. This filing is an amendment to correct a previous error, which is not uncommon. The pending business combination with Betaliq, Inc. is a significant event for Eyenovia, and the vesting of restricted stock units tied to this event aligns the director's interests with the company's success.

Comparison to Industry Standards

• Reverse stock splits are often undertaken by companies to increase their stock price to meet minimum listing requirements or to make the stock more attractive to institutional investors.
• The vesting of restricted stock units upon the completion of a merger or acquisition is a common practice to incentivize key personnel to remain with the company through the transition.
• Comparable companies in the pharmaceutical or biotechnology sectors often use similar equity-based compensation strategies to align management and shareholder interests.

Stakeholder Impact

• Shareholders: The correction of the filing ensures accurate information regarding insider ownership.
• Employees: The vesting of restricted stock units tied to the business combination can impact employee morale and retention.
• The business combination with Betaliq, Inc. could have a significant impact on the company's future prospects.

Next Steps

• Closing of the proposed business combination with Betaliq, Inc.
• Vesting of the restricted stock units upon the closing of the business combination and continued service of Charles E. Mather IV.

Key Dates

Keywords

Form 4/A, Eyenovia, Beneficial Ownership, Charles E. Mather IV, Reverse Stock Split, Betaliq, Director, Securities, Restricted Stock Units